<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01012167</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00044324</org_study_id>
    <secondary_id>1P50MH082999-01</secondary_id>
    <nct_id>NCT01012167</nct_id>
  </id_info>
  <brief_title>Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia</brief_title>
  <acronym>CIDAR-3</acronym>
  <official_title>Oxytocin or Galantamine vs. Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project is designed to address the following two primary aims:

        1. To determine whether adjunctive oxytocin is superior to placebo for the treatment of
           persistent negative symptoms, as measured by the SANS total score, in people with
           schizophrenia.

        2. To determine whether adjunctive Galantamine is superior to placebo for the treatment of
           cognitive impairments, as measured by improvement on a composite neurocognitive score in
           people with schizophrenia.

      The investigators will also address the following secondary aims:

        1. To determine whether people with schizophrenia treated with adjunctive oxytocin,
           compared to placebo, will show greater improvement on markers of negative symptom
           liability including: social affiliation, facial affect recognition, olfactory
           discrimination, initiation of smooth pursuit and latency of internally-driven saccades.

        2. To determine whether people with schizophrenia treated with adjunctive Galantamine,
           compared to placebo, will show greater improvement on markers of cognitive impairment
           liability including: predictive pursuit, P50 sensory gating and visual-spatial working
           memory.

      The investigators will address the following exploratory aims:

        1. To determine whether changes in markers of negative symptom liability are correlated
           with changes in SANS total score.

        2. To determine whether changes in markers of cognitive impairment liability are correlated
           with changes in the composite neurocognitive score.

        3. To determine the response to oxytocin of all cognition domains assessed by the MATRICS
           battery, and to determine the response to Galantamine of all cognition domains assessed
           by the MATRICS, which are not included in the primary neurocognitive outcome score.

        4. To determine whether there is a differential response of oxytocin and Galantamine on the
           SANS total score, composite neurocognitive score, and with the phenotypic measures of
           negative symptom and cognitive impairment liability.

        5. To determine whether oxytocin and Galantamine are associated with:

             -  adverse effects on positive or depressive symptoms;

             -  adverse effects on motor symptoms;

             -  adverse effects on laboratory and EKG measures;

             -  increased occurrence of side effects;

             -  social interest that is independent of sexual desire.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scale for the Assessment of Negative Symptoms (SANS) Total Score</measure>
    <time_frame>Every other week for 6 weeks</time_frame>
    <description>Mean SANS Total Score by Treatment and Week. SANS total score range = 0-85. Higher scores indicate more severe negative symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Z-Scores for Composite Cognitive Primary Outcome* by Treatment Group and Week</measure>
    <time_frame>Treatment Week 0 and Week 6</time_frame>
    <description>* Composite Cognitive Primary Outcome = mean of z-scores from the Brief Assessment of Cognition in Schizophrenia (BACS) Symbol Digit test, the Hopkins Verbal Learning Test (HVLT), and the Rapid Visual Information Processing test (RVIP). Z-scores for each test were calculated as Z = (individual patient score - pooled baseline mean)/(pooled baseline standard deviation). Higher values of the composite score represent a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scale for the Assessment of Negative Symptoms (SANS) - Avolition</measure>
    <time_frame>Every other week for 6 weeks</time_frame>
    <description>Mean score by treatment and week. Scores range from 0-5, with higher scores indicating a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scale for the Assessment of Negative Symptoms (SANS) - Anhedonia</measure>
    <time_frame>Every other week for 6 weeks</time_frame>
    <description>Mean score by treatment and week. Scores range from 0-5, with higher scores indicating a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scale for the Assessment of Negative Symptoms (SANS) - Alogia</measure>
    <time_frame>Every other week for 6 weeks</time_frame>
    <description>Mean score by treatment and week. Scores range from 0-5, with higher scores indicating a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scale for the Assessment of Negative Symptoms (SANS) - Blunted Affect</measure>
    <time_frame>Every other week for 6 weeks</time_frame>
    <description>Mean score by treatment and week. Scores range from 0-5, with higher scores indicating a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Psychiatric Rating Scale (BPRS) - Total Score</measure>
    <time_frame>Every other week for 6 weeks</time_frame>
    <description>The total BPRS score is calculated by adding the scores for scales #1-#18. Each scale ranges from &quot;1=Not Present&quot; to &quot;7=Very Severe&quot;. Total scores range from a minimum score of 18 to a maximum score of 126. A higher total score indicates a more severe psychiatric symptom rating.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Psychiatric Rating Scale (BPRS) - Psychosis Score</measure>
    <time_frame>Every other week for 6 weeks</time_frame>
    <description>The psychosis score is calculated by adding the scores for scales #4 Conceptual Disorganization, #11 Suspiciousness, #12 Hallucinatory Behavior, and #15 Unusual Thought Content. Each scale ranges from &quot;1=Not Present&quot; to &quot;7=Very Severe&quot;. The minimum psychosis score is 4 and the maximum psychosis score is 28. A higher score indicates a more severe psychosis rating.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calgary Depression Scale (CDS) - Total Score</measure>
    <time_frame>Every other week for 6 weeks</time_frame>
    <description>Total score calculated by adding scores for scales #1-#9. Each scale ranges from &quot;0=Absent&quot; to &quot;3=Severe&quot;. The minimum total CDS score is 0 and the maximum total CDS score is 27. A higher score indicates a more severe depression rating.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arizona Sexual Experience Questionnaire (ASEX) Female</measure>
    <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
    <description>Mean ASEX total scores by treatment and week for female participants. Total scores are calculated by adding scores for scales #1-#5. Each scale ranges from &quot;1=Easily/Extremely&quot; to &quot;6=Never/None&quot;. The minimum total ASEX score is 5 and the maximum score is 30. Lower scores indicate more positive sexual experiences.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arizona Sexual Experience Questionnaire (ASEX) Male</measure>
    <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
    <description>Mean ASEX total scores by treatment and week for male participants. Total scores are calculated by adding scores for scales #1-#5. Total scores are calculated by adding scores for scales #1-#5. Each scale ranges from &quot;1=Easily/Extremely&quot; to &quot;6=Never/None&quot;. The minimum total ASEX score is 5 and the maximum score is 30. Lower scores indicate more positive sexual experiences.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs - Diastolic Blood Pressure</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Mean diastolic blood pressure by treatment and follow-up week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs - Systolic Blood Pressure</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Mean systolic blood pressure by treatment and follow-up week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs - Weight</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Mean weight (kg) by treatment and follow-up week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs - Pulse</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Mean sitting pulse (bpm) by treatment and follow-up week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simpson-Angus Scale (SAS)</measure>
    <time_frame>Baseline, week 3, and week 6</time_frame>
    <description>SAS total score for extrapyramidal side effects: Frequencies of greatest within-participant increase (worsening) from pre-treatment baseline, by treatment group. Total scores calculated by adding scores from scales #1-#11. Each scale ranges from &quot;0=None/Normal&quot; to &quot;4=Extreme/Severe&quot;. The minimum total score is 0 and the maximum score is 44. Higher scores indicate a more severe extrapyramidal side effect rating.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal Involuntary Movement Scale (AIMS)</measure>
    <time_frame>Treatment Week 0 and Week 6</time_frame>
    <description>AIMS Total Score: Frequencies of Maximum Within- Participant Increases (worsening) from Baseline by Treatment Group. Total score calculated by adding scores from scales #1-#10. Each scale ranges from &quot;0=None&quot; to &quot;4=Severe&quot;. The minimum total AIMS score is 0 and the maximum score is 40. Higher scores indicate a more severe abnormal involuntary movement rating.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram (EKG)</measure>
    <time_frame>Once during Evaluation and once at Treatment Week 6</time_frame>
    <description>Mean corrected QT interval (QTc) by study week and treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barnes Akathisia Scale (BAS) - Global Score</measure>
    <time_frame>Treatment Week 0 and Week 6</time_frame>
    <description>For each subject, the largest increase from baseline in the global akathisia score at any visit during follow-up was calculated. The global akathisia score ranges from &quot;0=Absent&quot; to &quot;5=Severe Akathisia&quot;. Higher scores indicate a more severe global rating of akathisia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Oxytocin Levels</measure>
    <time_frame>Treatment Week 0 and Week 6</time_frame>
    <description>Blood Oxytocin Levels by Treatment and Visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Measures - ALT/SGPT</measure>
    <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
    <description>Alanine transaminase/serum glutamic-pyruvic transaminase (ALT/SGPT) blood levels by treatment group and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Measures - AST/SGOT</measure>
    <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
    <description>Aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) blood levels by treatment group and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Measures - Alkaline Phosphatase</measure>
    <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
    <description>Alkaline phosphatase blood level by treatment group and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Measures - Calcium</measure>
    <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
    <description>Calcium blood levels by treatment group and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Measures - Sodium</measure>
    <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
    <description>Sodium blood levels by treatment group and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Measures - Potassium</measure>
    <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
    <description>Potassium blood levels by treatment group and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Measures - Chloride</measure>
    <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
    <description>Chloride blood levels by treatment group and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Measures - CO2</measure>
    <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
    <description>Carbon Dioxide (CO2) blood levels by treatment group and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Measures - Cholesterol</measure>
    <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
    <description>Total cholesterol blood levels by treatment group and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Measures - HDL</measure>
    <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
    <description>High-density lipoprotein (HDL) blood levels by treatment group and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Measures - LDL</measure>
    <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
    <description>Low-density lipoprotein (LDL) blood levels by treatment group and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Measures - Triglycerides</measure>
    <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
    <description>Triglyceride blood levels by treatment group and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Measures - VLDL</measure>
    <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
    <description>Very low density lipoprotein (VLDL) blood levels by treatment group and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Measures - Glucose</measure>
    <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
    <description>Glucose blood levels by treatment group and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Measures - Albumin</measure>
    <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
    <description>Albumin blood levels by treatment group and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Measures - Globulin</measure>
    <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
    <description>Globulin blood levels by treatment group and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Measures - A/G Ratio</measure>
    <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
    <description>Albumin to Globulin (A/G) ratio in the blood by treatment group and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Measures - Bilirubin</measure>
    <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
    <description>Bilirubin blood level by treatment group and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Measures - Protein</measure>
    <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
    <description>Protein blood level by treatment group and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Measures - BUN</measure>
    <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
    <description>BUN blood level by treatment group and visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Abdominal Pain</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Abdominal Pain&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Anorexia</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Anorexia&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Bruising Easily</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Bruising Easily&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Constipation</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Constipation&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Diarrhea</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Diarrhea&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Dizziness</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Dizziness&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Dry Eye</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Dry Eye&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Dry Mouth</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Dry Mouth&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Enuresis</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Enuresis&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Excessive Tearing of the Eye</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Excessive Tearing of the Eye&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Fever</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Fever&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Headache</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Headache&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Hyperhydrosis</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Hyperhydrosis&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Hypersalivation</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Hypersalivation&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Insomnia</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Insomnia&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Malaise</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Malaise&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Mucosal Ulceration</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Mucosal Ulceration&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Nasal Irritation</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Nasal Irritation&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Nausea</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Nausea&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Rash</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Rash&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Restlessness</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Restlessness&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Sedation</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Sedation&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Sore Throat</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Sore Throat&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Stiffness</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Stiffness&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Tinnitus</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Tinnitus&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Tremor</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Tremor&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Urticaria</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Urticaria&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Uterine Contractions</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Uterine Contractions&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Vomiting</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Vomiting&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Weight Loss</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Weight Loss&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist (SEC) - Wheezing</measure>
    <time_frame>Weekly for 6 weeks</time_frame>
    <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Wheezing&quot; rating on the SEC, by Treatment Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Assessment Battery (MCCB) - Composite Score</measure>
    <time_frame>Once at Treatment Week 0 (baseline) and again at Treatment Week 6 (end of treatment).</time_frame>
    <description>MCCB Composite Score by Week ranging from -10-100 with a higher score indicating a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Assessment Battery (MCCB) - Attention Vigilance</measure>
    <time_frame>Once at Treatment Week 0 (baseline) and again at Treatment Week 6 (end of treatment).</time_frame>
    <description>MCCB Attention Vigilance domain score by week calculated from the Continuous Performance Test, Identical Pairs version. The domain score scale is 20-80, with higher scores indicating a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Assessment Battery (MCCB) - Processing Speed</measure>
    <time_frame>Once at Treatment Week 0 (baseline) and again at Treatment Week 6 (end of treatment).</time_frame>
    <description>MCCB Processing Speed domain score by week calculated from the Trail Making Test- Part A, Brief Assessment of Cognition in Schizophrenia- symbol coding subtest, and the Category fluency test- animal naming. The domain score scale is 20-80, with higher scores indicating a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Assessment Battery (MCCB) - Reasoning/Problem Solving</measure>
    <time_frame>Once at Treatment Week 0 (baseline) and again at Treatment Week 6 (end of treatment).</time_frame>
    <description>MCCB Reasoning/Problem Solving domain score by week calculated from the Neuropsychological Assessment Battery- mazes subtest. The domain score scale is 20-80, with higher scores indicating a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Assessment Battery (MCCB) - Social Cognition</measure>
    <time_frame>Once at Treatment Week 0 (baseline) and again at Treatment Week 6 (end of treatment).</time_frame>
    <description>MCCB Social Cognition domain score by week calculated from the Mayer-Salovey-Caruso Emotional Intelligence Test- managing emotions branch. The domain score scale is 20-80, with higher scores indicating a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Assessment Battery (MCCB) - Verbal Learning</measure>
    <time_frame>Once at Treatment Week 0 (baseline) and again at Treatment Week 6 (end of treatment).</time_frame>
    <description>MCCB Verbal Learning domain score by week calculated from the Hopkins Verbal Learning Test—Revised, immediate recall (three learning trials only). The domain score scale is 20-80, with higher scores indicating a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Assessment Battery (MCCB) - Visual Learning</measure>
    <time_frame>Once at Treatment Week 0 (baseline) and again at Treatment Week 6 (end of treatment).</time_frame>
    <description>MCCB Visual Learning domain score by week calculated from the Brief Visuospatial Memory Test—Revised. The domain score scale is 20-80, with higher scores indicating a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Assessment Battery (MCCB) - Working Memory</measure>
    <time_frame>Once at Treatment Week 0 (baseline) and again at Treatment Week 6 (end of treatment).</time_frame>
    <description>MCCB Working Memory domain score by week calculated from the Wechsler Memory Scale, 3rd ed., spatial span subtest. The domain score scale is 20-80, with higher scores indicating a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Affect Schedule (PANAS) - Negative</measure>
    <time_frame>Treatment Week 0 and Week 6</time_frame>
    <description>Participant reported responses after Brief Role Play rating how they felt during the role plays. Participants rated 12 negative affect items on a scale of 1-5, with 1 being &quot;very slightly or not at all&quot; and 5 being &quot;extremely&quot;. The minimum score for this measure is 12 and the maximum score is 60. Higher scores indicate a higher rate of negative affect during the role plays.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Affect Schedule (PANAS) - Positive</measure>
    <time_frame>Treatment Week 0 and Week 6</time_frame>
    <description>Participant reported responses after Brief Role Play rating how they felt during the role plays. Participants rated 12 positive affect items on a scale of 1-5, with 1 being &quot;very slightly or not at all&quot; and 5 being &quot;extremely&quot;. The minimum score for this measure is 12 and the maximum score is 60. Higher scores indicate a higher rate of positive affect during the role plays.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactions to Partner</measure>
    <time_frame>Treatment Week 0 and Week 6</time_frame>
    <description>Participant reported responses after Brief Role Play. The Reactions to Partner item was calculated by totaling responses to 7 scales. Each scale score ranges from 1-5, which 1 being &quot;completely agree&quot; and 5 being &quot;completely disagree&quot;. The minimum score for this measure is 7 and the maximum score is 35. Higher responses indicate a more negative reaction to their role play partner.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Willingness to Interact</measure>
    <time_frame>Treatment Week 0 and Week 6</time_frame>
    <description>Participant reported responses after Brief Role Play. The Willingness to Interact item calculated by totaling scores from items 1-6. Each score ranges from 1-5, with 1 being &quot;definitely willing&quot; and 5 being &quot;definitely unwilling&quot;. The minimum score for this measure is 6 and the maximum score is 30. Lower scores indicate more willingness to interact with their role play partner again in the future.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>1: galantamine/placebo-oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: oxytocin/placebo-galantamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3: placebo-galantamine /placebo-oxytocin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Oxytocin: 24 IU in the morning and 24 IU in the evening given by nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration</description>
    <arm_group_label>2: oxytocin/placebo-galantamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galantamine</intervention_name>
    <description>Galantamine: 4 mg twice a day for 1 week, then 8 mg twice a day for 1 week, then 12 mg twice a day for 4 weeks</description>
    <arm_group_label>1: galantamine/placebo-oxytocin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo-Oxytocin</intervention_name>
    <description>Saline nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration</description>
    <arm_group_label>1: galantamine/placebo-oxytocin</arm_group_label>
    <arm_group_label>3: placebo-galantamine /placebo-oxytocin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo-Galantamine</intervention_name>
    <description>Placebo tablets twice a day for 6 weeks</description>
    <arm_group_label>2: oxytocin/placebo-galantamine</arm_group_label>
    <arm_group_label>3: placebo-galantamine /placebo-oxytocin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any race

          -  Subjects will meet DSM-IV criteria for schizophrenia or schizoaffective disorder

          -  Judged clinically stable and will not exceed threshold levels of positive, depressive,
             and/or extrapyramidal symptoms

          -  The minimum level of negative symptoms will be defined as follows:

               -  Scale for the Assessment of Negative Symptoms (SANS) total score (minus the
                  global items, and inappropriate affect, poverty of content of speech and
                  attentional items) 20 or greater; OR

               -  SANS alogia global item score 3 or greater

          -  The maximum level of psychotic, depressive, and extrapyramidal symptoms at the
             beginning and end of leading in:

               -  Brief Psychiatric Rating Scale (BPRS) psychotic factor score (4-items) less or
                  equal to 16

               -  BPRS Anxiety/Depression factor score (4-items) less than or equal to 14

               -  Simpson-Angus-Scale (SAS) total score (13-items) less than or equal to 10

          -  Subjects will be required to be on the same antipsychotic(s) for two months and on the
             same dose for the last month

        Exclusion Criteria:

          -  Participants with an organic brain disorder; mental retardation; or a medical
             condition, whose pathology or treatment could alter the presentation or treatment of
             schizophrenia or significantly increase the risk associated with the proposed
             treatment protocol

          -  Participants with intermittent alcohol or substance use will not be excluded unless
             they have met DSM-IV criteria for alcohol or substance abuse (other than nicotine)
             within the last month.

          -  Participants may be treated with one or more antipsychotics, except chlorpromazine,
             thioridazine, or mesoridazine. These latter antipsychotics are excluded because of the
             concern that their anticholinergic properties may interfere with the accurate
             assessment of galantamine efficacy.

          -  Participants may not be treated with anticholinergic medications or have clinically
             significant extrapyramidal symptoms. Additionally, subjects treated with
             glycopyrrolate will be accepted.

          -  Female participants may not be pregnant

          -  Female subjects may not be taking olanzapine at doses higher than 30 mg . Male
             subjects may not be taking olanzapine at doses higher than 40 mg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William T Carpenter, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baltimore VA Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Mental Health Centers</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keypoint Community Mental Health Centers</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Psychiatric Research Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Psychiatric Research Center</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keypoint Mental health Center</name>
      <address>
        <city>Dundalk</city>
        <state>Maryland</state>
        <zip>21222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2009</study_first_submitted>
  <study_first_submitted_qc>November 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2009</study_first_posted>
  <results_first_submitted>May 25, 2016</results_first_submitted>
  <results_first_submitted_qc>May 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 2, 2017</results_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>William Carpenter</investigator_full_name>
    <investigator_title>Director, Maryland Psychiatric Research Center, Outpatient Research Program</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia, oxytocin, galantamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Galantamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Consented/Screened for Study-- N=86
Withdrew prior to randomization (N=28)
2 withdrew consent
26 did not meet inclusion criteria
Randomized-- N=58</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1: Oxytocin/Placebo-galantamine</title>
          <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
        </group>
        <group group_id="P2">
          <title>2: Galantamine/Placebo-oxytocin</title>
          <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
        </group>
        <group group_id="P3">
          <title>3: Placebo-galantamine /Placebo-oxytocin</title>
          <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Withdrawn Prior to Study Drug Exposure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Exposed to Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Number of participants randomized N=58
Withdrawn prior to exposure to study drug (N=2) Oxytocin N=1 withdrawn due to abnormal EKG Placebo N=1 Participant withdrew consent
Exposed to study drug N=56</population>
      <group_list>
        <group group_id="B1">
          <title>1: Oxytocin</title>
          <description>Oxytocin: 24 IU oxytocin or placebo in a total of 6 puffs (3 puffs per nostril)daily for 6 weeks</description>
        </group>
        <group group_id="B2">
          <title>2: Galantamine</title>
          <description>Galantamine or placebo Galantamine: Galantamine will be dispensed as follows: 4 mg bid x 7 days; 8mg bid x 7days, then 12 mg bid for the last 4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>3: Placebo</title>
          <description>Placebo: placebo-Galantamine 1 capsules twice a day and placebo-oxytocin 3 puffs in each nostril once a day.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.4" spread="11.2"/>
                    <measurement group_id="B2" value="45.8" spread="12.4"/>
                    <measurement group_id="B3" value="42.2" spread="11.7"/>
                    <measurement group_id="B4" value="44.9" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Scale for the Assessment of Negative Symptoms (SANS) Total Score</title>
        <description>Mean SANS Total Score by Treatment and Week. SANS total score range = 0-85. Higher scores indicate more severe negative symptoms.</description>
        <time_frame>Every other week for 6 weeks</time_frame>
        <population>Of the 56 participants exposed to study drug, 3 withdrew before any efficacy data was collected, leaving 53 for whom at least some interim efficacy data was collected. Participants had to complete at least two weeks follow-up to be included in the symptom analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin/Placebo-galantamine</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine/Placebo-oxytocin</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo-galantamine /Placebo-oxytocin</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Scale for the Assessment of Negative Symptoms (SANS) Total Score</title>
          <description>Mean SANS Total Score by Treatment and Week. SANS total score range = 0-85. Higher scores indicate more severe negative symptoms.</description>
          <population>Of the 56 participants exposed to study drug, 3 withdrew before any efficacy data was collected, leaving 53 for whom at least some interim efficacy data was collected. Participants had to complete at least two weeks follow-up to be included in the symptom analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.23" spread="6.91"/>
                    <measurement group_id="O2" value="36.63" spread="10.09"/>
                    <measurement group_id="O3" value="36.63" spread="10.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.07" spread="6.93"/>
                    <measurement group_id="O2" value="35.22" spread="10.97"/>
                    <measurement group_id="O3" value="35.05" spread="10.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.27" spread="7.53"/>
                    <measurement group_id="O2" value="34.06" spread="10.26"/>
                    <measurement group_id="O3" value="34.22" spread="9.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.40" spread="6.85"/>
                    <measurement group_id="O2" value="33.22" spread="10.64"/>
                    <measurement group_id="O3" value="33.47" spread="8.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Week 0 at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.17" spread="4.20"/>
                    <measurement group_id="O2" value="-1.41" spread="3.32"/>
                    <measurement group_id="O3" value="-1.58" spread="4.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Week 0 at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.97" spread="4.48"/>
                    <measurement group_id="O2" value="-1.69" spread="3.46"/>
                    <measurement group_id="O3" value="-1.47" spread="5.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Week 0 at Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.83" spread="3.74"/>
                    <measurement group_id="O2" value="-2.53" spread="4.34"/>
                    <measurement group_id="O3" value="-1.00" spread="4.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Z-Scores for Composite Cognitive Primary Outcome* by Treatment Group and Week</title>
        <description>* Composite Cognitive Primary Outcome = mean of z-scores from the Brief Assessment of Cognition in Schizophrenia (BACS) Symbol Digit test, the Hopkins Verbal Learning Test (HVLT), and the Rapid Visual Information Processing test (RVIP). Z-scores for each test were calculated as Z = (individual patient score - pooled baseline mean)/(pooled baseline standard deviation). Higher values of the composite score represent a better outcome.</description>
        <time_frame>Treatment Week 0 and Week 6</time_frame>
        <population>Five subjects were unable to handle the demands of the Rapid Visual Information Processing (RVIP) test, part of the composite primary outcome measure, and did not provide valid data.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin/Placebo-galantamine</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine/Placebo-oxytocin</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo-galantamine /Placebo-oxytocin</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Z-Scores for Composite Cognitive Primary Outcome* by Treatment Group and Week</title>
          <description>* Composite Cognitive Primary Outcome = mean of z-scores from the Brief Assessment of Cognition in Schizophrenia (BACS) Symbol Digit test, the Hopkins Verbal Learning Test (HVLT), and the Rapid Visual Information Processing test (RVIP). Z-scores for each test were calculated as Z = (individual patient score - pooled baseline mean)/(pooled baseline standard deviation). Higher values of the composite score represent a better outcome.</description>
          <population>Five subjects were unable to handle the demands of the Rapid Visual Information Processing (RVIP) test, part of the composite primary outcome measure, and did not provide valid data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.92"/>
                    <measurement group_id="O2" value="-0.22" spread="0.47"/>
                    <measurement group_id="O3" value="0.21" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="1"/>
                    <measurement group_id="O2" value="-0.05" spread="0.68"/>
                    <measurement group_id="O3" value="0.18" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.37"/>
                    <measurement group_id="O2" value="0.17" spread="0.44"/>
                    <measurement group_id="O3" value="0.03" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Scale for the Assessment of Negative Symptoms (SANS) - Avolition</title>
        <description>Mean score by treatment and week. Scores range from 0-5, with higher scores indicating a worse outcome.</description>
        <time_frame>Every other week for 6 weeks</time_frame>
        <population>Of the 56 participants exposed to study drug, 3 withdrew before any efficacy data was collected, leaving 53 for whom at least some interim efficacy data was collected. Participants had to complete at least two weeks follow-up to be included in the symptom analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin/Placebo-galantamine</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine/Placebo-oxytocin</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo-galantamine /Placebo-oxytocin</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Scale for the Assessment of Negative Symptoms (SANS) - Avolition</title>
          <description>Mean score by treatment and week. Scores range from 0-5, with higher scores indicating a worse outcome.</description>
          <population>Of the 56 participants exposed to study drug, 3 withdrew before any efficacy data was collected, leaving 53 for whom at least some interim efficacy data was collected. Participants had to complete at least two weeks follow-up to be included in the symptom analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.94" spread="0.90"/>
                    <measurement group_id="O2" value="2.91" spread="0.88"/>
                    <measurement group_id="O3" value="2.44" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.78" spread="0.77"/>
                    <measurement group_id="O2" value="2.73" spread="0.74"/>
                    <measurement group_id="O3" value="2.43" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" spread="1.04"/>
                    <measurement group_id="O2" value="2.74" spread=".084"/>
                    <measurement group_id="O3" value="2.44" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88" spread="0.89"/>
                    <measurement group_id="O2" value="2.74" spread="0.90"/>
                    <measurement group_id="O3" value="2.41" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Week 0 at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.32"/>
                    <measurement group_id="O2" value="-0.18" spread="0.43"/>
                    <measurement group_id="O3" value="-0.01" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Week 0 at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.31"/>
                    <measurement group_id="O2" value="-0.16" spread="0.50"/>
                    <measurement group_id="O3" value="0.04" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Week 0 at Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.48"/>
                    <measurement group_id="O2" value="-0.16" spread="0.69"/>
                    <measurement group_id="O3" value="0.05" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Scale for the Assessment of Negative Symptoms (SANS) - Anhedonia</title>
        <description>Mean score by treatment and week. Scores range from 0-5, with higher scores indicating a worse outcome.</description>
        <time_frame>Every other week for 6 weeks</time_frame>
        <population>Of the 56 participants exposed to study drug, 3 withdrew before any efficacy data was collected, leaving 53 for whom at least some interim efficacy data was collected. Participants had to complete at least two weeks follow-up to be included in the symptom analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin/Placebo-galantamine</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine/Placebo-oxytocin</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo-galantamine /Placebo-oxytocin</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Scale for the Assessment of Negative Symptoms (SANS) - Anhedonia</title>
          <description>Mean score by treatment and week. Scores range from 0-5, with higher scores indicating a worse outcome.</description>
          <population>Of the 56 participants exposed to study drug, 3 withdrew before any efficacy data was collected, leaving 53 for whom at least some interim efficacy data was collected. Participants had to complete at least two weeks follow-up to be included in the symptom analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.42" spread="0.59"/>
                    <measurement group_id="O2" value="2.60" spread="0.80"/>
                    <measurement group_id="O3" value="2.66" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.42" spread="0.64"/>
                    <measurement group_id="O2" value="2.59" spread="0.86"/>
                    <measurement group_id="O3" value="2.58" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.27" spread="0.78"/>
                    <measurement group_id="O2" value="2.46" spread="0.99"/>
                    <measurement group_id="O3" value="2.60" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="0.49"/>
                    <measurement group_id="O2" value="2.43" spread="0.98"/>
                    <measurement group_id="O3" value="2.66" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Week 0 at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.37"/>
                    <measurement group_id="O2" value="-0.01" spread="0.40"/>
                    <measurement group_id="O3" value="-0.08" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Week 0 at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.68"/>
                    <measurement group_id="O2" value="-0.11" spread=".013"/>
                    <measurement group_id="O3" value="0.01" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Week 0 at Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.38"/>
                    <measurement group_id="O2" value="-0.14" spread="0.38"/>
                    <measurement group_id="O3" value="0.12" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Scale for the Assessment of Negative Symptoms (SANS) - Alogia</title>
        <description>Mean score by treatment and week. Scores range from 0-5, with higher scores indicating a worse outcome.</description>
        <time_frame>Every other week for 6 weeks</time_frame>
        <population>Of the 56 participants exposed to study drug, 3 withdrew before any efficacy data was collected, leaving 53 for whom at least some interim efficacy data was collected. Participants had to complete at least two weeks follow-up to be included in the symptom analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin/Placebo-galantamine</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine/Placebo-oxytocin</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo-galantamine /Placebo-oxytocin</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Scale for the Assessment of Negative Symptoms (SANS) - Alogia</title>
          <description>Mean score by treatment and week. Scores range from 0-5, with higher scores indicating a worse outcome.</description>
          <population>Of the 56 participants exposed to study drug, 3 withdrew before any efficacy data was collected, leaving 53 for whom at least some interim efficacy data was collected. Participants had to complete at least two weeks follow-up to be included in the symptom analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="0.61"/>
                    <measurement group_id="O2" value="0.95" spread="0.65"/>
                    <measurement group_id="O3" value="0.99" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.67"/>
                    <measurement group_id="O2" value="0.89" spread="0.59"/>
                    <measurement group_id="O3" value="0.89" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.70"/>
                    <measurement group_id="O2" value="0.85" spread="0.50"/>
                    <measurement group_id="O3" value="0.80" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.69"/>
                    <measurement group_id="O2" value="0.78" spread="0.44"/>
                    <measurement group_id="O3" value="0.69" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Week 0 at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.42"/>
                    <measurement group_id="O2" value="-0.05" spread="0.36"/>
                    <measurement group_id="O3" value="-0.10" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Week 0 at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.41"/>
                    <measurement group_id="O2" value="-0.03" spread="0.37"/>
                    <measurement group_id="O3" value="-0.17" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Week 0 at Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.46"/>
                    <measurement group_id="O2" value="-0.10" spread="0.31"/>
                    <measurement group_id="O3" value="-0.19" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Scale for the Assessment of Negative Symptoms (SANS) - Blunted Affect</title>
        <description>Mean score by treatment and week. Scores range from 0-5, with higher scores indicating a worse outcome.</description>
        <time_frame>Every other week for 6 weeks</time_frame>
        <population>Of the 56 participants exposed to study drug, 3 withdrew before any efficacy data was collected, leaving 53 for whom at least some interim efficacy data was collected. Participants had to complete at least two weeks follow-up to be included in the symptom analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin/Placebo-galantamine</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine/Placebo-oxytocin</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo-galantamine /Placebo-oxytocin</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Scale for the Assessment of Negative Symptoms (SANS) - Blunted Affect</title>
          <description>Mean score by treatment and week. Scores range from 0-5, with higher scores indicating a worse outcome.</description>
          <population>Of the 56 participants exposed to study drug, 3 withdrew before any efficacy data was collected, leaving 53 for whom at least some interim efficacy data was collected. Participants had to complete at least two weeks follow-up to be included in the symptom analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.86"/>
                    <measurement group_id="O2" value="1.96" spread="1.06"/>
                    <measurement group_id="O3" value="2.21" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="0.90"/>
                    <measurement group_id="O2" value="1.89" spread="1.10"/>
                    <measurement group_id="O3" value="2.05" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" spread="0.91"/>
                    <measurement group_id="O2" value="1.79" spread="0.99"/>
                    <measurement group_id="O3" value="1.94" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="0.96"/>
                    <measurement group_id="O2" value="1.70" spread="1.05"/>
                    <measurement group_id="O3" value="1.85" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Week 0 at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.36"/>
                    <measurement group_id="O2" value="-0.07" spread="0.36"/>
                    <measurement group_id="O3" value="-0.16" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Week 0 at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.44"/>
                    <measurement group_id="O2" value="-0.09" spread="0.33"/>
                    <measurement group_id="O3" value="-0.19" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Week 0 at Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.36"/>
                    <measurement group_id="O2" value="-0.17" spread="0.40"/>
                    <measurement group_id="O3" value="-0.19" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Psychiatric Rating Scale (BPRS) - Total Score</title>
        <description>The total BPRS score is calculated by adding the scores for scales #1-#18. Each scale ranges from &quot;1=Not Present&quot; to &quot;7=Very Severe&quot;. Total scores range from a minimum score of 18 to a maximum score of 126. A higher total score indicates a more severe psychiatric symptom rating.</description>
        <time_frame>Every other week for 6 weeks</time_frame>
        <population>Safety data available for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin/Placebo-galantamine</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine/Placebo-oxytocin</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo-galantamine /Placebo-oxytocin</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Psychiatric Rating Scale (BPRS) - Total Score</title>
          <description>The total BPRS score is calculated by adding the scores for scales #1-#18. Each scale ranges from &quot;1=Not Present&quot; to &quot;7=Very Severe&quot;. Total scores range from a minimum score of 18 to a maximum score of 126. A higher total score indicates a more severe psychiatric symptom rating.</description>
          <population>Safety data available for 56 participants exposed to study treatment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.16" spread="5.66"/>
                    <measurement group_id="O2" value="30.35" spread="6.66"/>
                    <measurement group_id="O3" value="32.65" spread="7.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.00" spread="7.46"/>
                    <measurement group_id="O2" value="28.95" spread="7.83"/>
                    <measurement group_id="O3" value="31.75" spread="7.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.07" spread="6.15"/>
                    <measurement group_id="O2" value="27.83" spread="6.88"/>
                    <measurement group_id="O3" value="31.72" spread="7.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.33" spread="5.09"/>
                    <measurement group_id="O2" value="27.67" spread="6.42"/>
                    <measurement group_id="O3" value="32.18" spread="6.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Psychiatric Rating Scale (BPRS) - Psychosis Score</title>
        <description>The psychosis score is calculated by adding the scores for scales #4 Conceptual Disorganization, #11 Suspiciousness, #12 Hallucinatory Behavior, and #15 Unusual Thought Content. Each scale ranges from &quot;1=Not Present&quot; to &quot;7=Very Severe&quot;. The minimum psychosis score is 4 and the maximum psychosis score is 28. A higher score indicates a more severe psychosis rating.</description>
        <time_frame>Every other week for 6 weeks</time_frame>
        <population>Safety data available for the 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Oxytocin: 24 IU oxytocin or placebo in a total of 6 puffs (3 puffs per nostril)daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Galantamine or placebo Galantamine: Galantamine will be dispensed as follows: 4 mg bid x 7 days; 8mg bid x 7days, then 12 mg bid for the last 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Placebo: placebo-Galantamine 1 capsules twice a day and placebo-oxytocin 3 puffs in each nostril once a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Psychiatric Rating Scale (BPRS) - Psychosis Score</title>
          <description>The psychosis score is calculated by adding the scores for scales #4 Conceptual Disorganization, #11 Suspiciousness, #12 Hallucinatory Behavior, and #15 Unusual Thought Content. Each scale ranges from &quot;1=Not Present&quot; to &quot;7=Very Severe&quot;. The minimum psychosis score is 4 and the maximum psychosis score is 28. A higher score indicates a more severe psychosis rating.</description>
          <population>Safety data available for the 56 participants exposed to study treatment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.34" spread="3.20"/>
                    <measurement group_id="O2" value="7.30" spread="3.01"/>
                    <measurement group_id="O3" value="8.18" spread="3.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.40" spread="3.79"/>
                    <measurement group_id="O2" value="7.21" spread="3.61"/>
                    <measurement group_id="O3" value="7.90" spread="3.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.87" spread="3.60"/>
                    <measurement group_id="O2" value="7.00" spread="3.48"/>
                    <measurement group_id="O3" value="8.06" spread="4.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.67" spread="2.87"/>
                    <measurement group_id="O2" value="6.78" spread="3.21"/>
                    <measurement group_id="O3" value="7.59" spread="4.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Calgary Depression Scale (CDS) - Total Score</title>
        <description>Total score calculated by adding scores for scales #1-#9. Each scale ranges from &quot;0=Absent&quot; to &quot;3=Severe&quot;. The minimum total CDS score is 0 and the maximum total CDS score is 27. A higher score indicates a more severe depression rating.</description>
        <time_frame>Every other week for 6 weeks</time_frame>
        <population>Of the 56 participants exposed to study drug, 3 withdrew before any efficacy data was collected, leaving 53 for whom at least some interim efficacy data was collected. Participants had to complete at least two weeks follow-up to be included in the symptom analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin/Placebo-galantamine</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine/Placebo-oxytocin</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo-galantamine /Placebo-oxytocin</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Calgary Depression Scale (CDS) - Total Score</title>
          <description>Total score calculated by adding scores for scales #1-#9. Each scale ranges from &quot;0=Absent&quot; to &quot;3=Severe&quot;. The minimum total CDS score is 0 and the maximum total CDS score is 27. A higher score indicates a more severe depression rating.</description>
          <population>Of the 56 participants exposed to study drug, 3 withdrew before any efficacy data was collected, leaving 53 for whom at least some interim efficacy data was collected. Participants had to complete at least two weeks follow-up to be included in the symptom analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" spread="2.70"/>
                    <measurement group_id="O2" value="0.84" spread="1.07"/>
                    <measurement group_id="O3" value="1.59" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.20" spread="2.54"/>
                    <measurement group_id="O2" value="1.05" spread="1.65"/>
                    <measurement group_id="O3" value="1.00" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" spread="2.13"/>
                    <measurement group_id="O2" value="0.67" spread="1.28"/>
                    <measurement group_id="O3" value="0.94" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="2.47"/>
                    <measurement group_id="O2" value="0.50" spread="0.71"/>
                    <measurement group_id="O3" value="1.29" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arizona Sexual Experience Questionnaire (ASEX) Female</title>
        <description>Mean ASEX total scores by treatment and week for female participants. Total scores are calculated by adding scores for scales #1-#5. Each scale ranges from &quot;1=Easily/Extremely&quot; to &quot;6=Never/None&quot;. The minimum total ASEX score is 5 and the maximum score is 30. Lower scores indicate more positive sexual experiences.</description>
        <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
        <population>Female participants who completed at least two weeks follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin/Placebo-galantamine</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine/Placebo-oxytocin</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo-galantamine /Placebo-oxytocin</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Arizona Sexual Experience Questionnaire (ASEX) Female</title>
          <description>Mean ASEX total scores by treatment and week for female participants. Total scores are calculated by adding scores for scales #1-#5. Each scale ranges from &quot;1=Easily/Extremely&quot; to &quot;6=Never/None&quot;. The minimum total ASEX score is 5 and the maximum score is 30. Lower scores indicate more positive sexual experiences.</description>
          <population>Female participants who completed at least two weeks follow-up.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="0.7"/>
                    <measurement group_id="O2" value="21.2" spread="7.6"/>
                    <measurement group_id="O3" value="29.0" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="0.7"/>
                    <measurement group_id="O2" value="19.2" spread="9.3"/>
                    <measurement group_id="O3" value="30.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="0.0"/>
                    <measurement group_id="O2" value="-2.0" spread="3.5"/>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arizona Sexual Experience Questionnaire (ASEX) Male</title>
        <description>Mean ASEX total scores by treatment and week for male participants. Total scores are calculated by adding scores for scales #1-#5. Total scores are calculated by adding scores for scales #1-#5. Each scale ranges from &quot;1=Easily/Extremely&quot; to &quot;6=Never/None&quot;. The minimum total ASEX score is 5 and the maximum score is 30. Lower scores indicate more positive sexual experiences.</description>
        <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
        <population>Male participants who completed at least two weeks follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin/Placebo-galantamine</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine/Placebo-oxytocin</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo-galantamine /Placebo-oxytocin</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Arizona Sexual Experience Questionnaire (ASEX) Male</title>
          <description>Mean ASEX total scores by treatment and week for male participants. Total scores are calculated by adding scores for scales #1-#5. Total scores are calculated by adding scores for scales #1-#5. Each scale ranges from &quot;1=Easily/Extremely&quot; to &quot;6=Never/None&quot;. The minimum total ASEX score is 5 and the maximum score is 30. Lower scores indicate more positive sexual experiences.</description>
          <population>Male participants who completed at least two weeks follow-up.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" spread="9.2"/>
                    <measurement group_id="O2" value="18.1" spread="6.7"/>
                    <measurement group_id="O3" value="20.8" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" spread="8.5"/>
                    <measurement group_id="O2" value="20.2" spread="7.5"/>
                    <measurement group_id="O3" value="21.7" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="7.8"/>
                    <measurement group_id="O2" value="1.6" spread="5.0"/>
                    <measurement group_id="O3" value="0.8" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs - Diastolic Blood Pressure</title>
        <description>Mean diastolic blood pressure by treatment and follow-up week</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin/Placebo-galantamine</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine/Placebo-oxytocin</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo-galantamine /Placebo-oxytocin</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Diastolic Blood Pressure</title>
          <description>Mean diastolic blood pressure by treatment and follow-up week</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>mm-Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.8" spread="8.3"/>
                    <measurement group_id="O2" value="76.6" spread="10.7"/>
                    <measurement group_id="O3" value="78.3" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.4" spread="9.0"/>
                    <measurement group_id="O2" value="76.2" spread="8.9"/>
                    <measurement group_id="O3" value="75.5" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.7" spread="9.1"/>
                    <measurement group_id="O2" value="77.5" spread="8.4"/>
                    <measurement group_id="O3" value="79.7" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" spread="10.6"/>
                    <measurement group_id="O2" value="79.1" spread="6.9"/>
                    <measurement group_id="O3" value="78.9" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.9" spread="8.2"/>
                    <measurement group_id="O2" value="75.1" spread="7.3"/>
                    <measurement group_id="O3" value="73.7" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2" spread="8.8"/>
                    <measurement group_id="O2" value="79.2" spread="8.4"/>
                    <measurement group_id="O3" value="77.2" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.4" spread="8.3"/>
                    <measurement group_id="O2" value="80.7" spread="6.9"/>
                    <measurement group_id="O3" value="76.0" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs - Systolic Blood Pressure</title>
        <description>Mean systolic blood pressure by treatment and follow-up week</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin/Placebo-galantamine</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine/Placebo-oxytocin</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo-galantamine /Placebo-oxytocin</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Systolic Blood Pressure</title>
          <description>Mean systolic blood pressure by treatment and follow-up week</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>mm-Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.4" spread="16.7"/>
                    <measurement group_id="O2" value="123.4" spread="17.3"/>
                    <measurement group_id="O3" value="132.3" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.1" spread="16.9"/>
                    <measurement group_id="O2" value="123.9" spread="15.0"/>
                    <measurement group_id="O3" value="127.4" spread="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.9" spread="20.5"/>
                    <measurement group_id="O2" value="123.7" spread="13.8"/>
                    <measurement group_id="O3" value="136.2" spread="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.5" spread="21.1"/>
                    <measurement group_id="O2" value="127.3" spread="19.0"/>
                    <measurement group_id="O3" value="137.7" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.8" spread="17.3"/>
                    <measurement group_id="O2" value="123.8" spread="19.0"/>
                    <measurement group_id="O3" value="129.9" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.4" spread="20.5"/>
                    <measurement group_id="O2" value="126.9" spread="20.1"/>
                    <measurement group_id="O3" value="132.8" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.0" spread="17.5"/>
                    <measurement group_id="O2" value="129.6" spread="16.1"/>
                    <measurement group_id="O3" value="134.5" spread="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs - Weight</title>
        <description>Mean weight (kg) by treatment and follow-up week</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin/Placebo-galantamine</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine/Placebo-oxytocin</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo-galantamine /Placebo-oxytocin</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Weight</title>
          <description>Mean weight (kg) by treatment and follow-up week</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.5" spread="18.4"/>
                    <measurement group_id="O2" value="96.2" spread="16.2"/>
                    <measurement group_id="O3" value="96.4" spread="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" spread="19.1"/>
                    <measurement group_id="O2" value="97.5" spread="16.0"/>
                    <measurement group_id="O3" value="97.9" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0" spread="18.9"/>
                    <measurement group_id="O2" value="97.5" spread="16.1"/>
                    <measurement group_id="O3" value="98.3" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0" spread="18.9"/>
                    <measurement group_id="O2" value="94.5" spread="13.8"/>
                    <measurement group_id="O3" value="98.4" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" spread="17.9"/>
                    <measurement group_id="O2" value="95.5" spread="14.4"/>
                    <measurement group_id="O3" value="100.3" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" spread="18.6"/>
                    <measurement group_id="O2" value="94.0" spread="14.6"/>
                    <measurement group_id="O3" value="100.8" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" spread="18.0"/>
                    <measurement group_id="O2" value="95.1" spread="14.7"/>
                    <measurement group_id="O3" value="97.9" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs - Pulse</title>
        <description>Mean sitting pulse (bpm) by treatment and follow-up week</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin/Placebo-galantamine</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine/Placebo-oxytocin</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo-galantamine /Placebo-oxytocin</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Pulse</title>
          <description>Mean sitting pulse (bpm) by treatment and follow-up week</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.2" spread="10.4"/>
                    <measurement group_id="O2" value="86.0" spread="14.1"/>
                    <measurement group_id="O3" value="85.2" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2" spread="18.8"/>
                    <measurement group_id="O2" value="91.6" spread="14.9"/>
                    <measurement group_id="O3" value="89.3" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.7" spread="17.3"/>
                    <measurement group_id="O2" value="91.3" spread="14.2"/>
                    <measurement group_id="O3" value="87.3" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5" spread="11.5"/>
                    <measurement group_id="O2" value="89.2" spread="15.6"/>
                    <measurement group_id="O3" value="89.2" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.6" spread="13.2"/>
                    <measurement group_id="O2" value="88.6" spread="12.9"/>
                    <measurement group_id="O3" value="83.7" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.4" spread="13.2"/>
                    <measurement group_id="O2" value="98.6" spread="28.1"/>
                    <measurement group_id="O3" value="90.5" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.1" spread="15.0"/>
                    <measurement group_id="O2" value="85.2" spread="16.6"/>
                    <measurement group_id="O3" value="84.7" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Simpson-Angus Scale (SAS)</title>
        <description>SAS total score for extrapyramidal side effects: Frequencies of greatest within-participant increase (worsening) from pre-treatment baseline, by treatment group. Total scores calculated by adding scores from scales #1-#11. Each scale ranges from &quot;0=None/Normal&quot; to &quot;4=Extreme/Severe&quot;. The minimum total score is 0 and the maximum score is 44. Higher scores indicate a more severe extrapyramidal side effect rating.</description>
        <time_frame>Baseline, week 3, and week 6</time_frame>
        <population>Of the 56 participants exposed to study drug, 3 withdrew before any efficacy data was collected, leaving 53 for whom at least some interim efficacy data was collected. Participants had to complete at least two weeks follow-up to be included in the symptom analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin/Placebo-galantamine</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine/Placebo-oxytocin</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo-galantamine /Placebo-oxytocin</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Simpson-Angus Scale (SAS)</title>
          <description>SAS total score for extrapyramidal side effects: Frequencies of greatest within-participant increase (worsening) from pre-treatment baseline, by treatment group. Total scores calculated by adding scores from scales #1-#11. Each scale ranges from &quot;0=None/Normal&quot; to &quot;4=Extreme/Severe&quot;. The minimum total score is 0 and the maximum score is 44. Higher scores indicate a more severe extrapyramidal side effect rating.</description>
          <population>Of the 56 participants exposed to study drug, 3 withdrew before any efficacy data was collected, leaving 53 for whom at least some interim efficacy data was collected. Participants had to complete at least two weeks follow-up to be included in the symptom analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No worsening (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="63.16"/>
                    <measurement group_id="O3" value="78.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsening of 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67"/>
                    <measurement group_id="O2" value="10.53"/>
                    <measurement group_id="O3" value="10.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsening of 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67"/>
                    <measurement group_id="O2" value="15.79"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsening of 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67"/>
                    <measurement group_id="O2" value="5.26"/>
                    <measurement group_id="O3" value="5.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsening of 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5.26"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsening of 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Abnormal Involuntary Movement Scale (AIMS)</title>
        <description>AIMS Total Score: Frequencies of Maximum Within- Participant Increases (worsening) from Baseline by Treatment Group. Total score calculated by adding scores from scales #1-#10. Each scale ranges from &quot;0=None&quot; to &quot;4=Severe&quot;. The minimum total AIMS score is 0 and the maximum score is 40. Higher scores indicate a more severe abnormal involuntary movement rating.</description>
        <time_frame>Treatment Week 0 and Week 6</time_frame>
        <population>50 participants who completed the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin/Placebo-galantamine</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine/Placebo-oxytocin</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo-galantamine /Placebo-oxytocin</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Abnormal Involuntary Movement Scale (AIMS)</title>
          <description>AIMS Total Score: Frequencies of Maximum Within- Participant Increases (worsening) from Baseline by Treatment Group. Total score calculated by adding scores from scales #1-#10. Each scale ranges from &quot;0=None&quot; to &quot;4=Severe&quot;. The minimum total AIMS score is 0 and the maximum score is 40. Higher scores indicate a more severe abnormal involuntary movement rating.</description>
          <population>50 participants who completed the trial.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No worsening (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.67"/>
                    <measurement group_id="O2" value="77.78"/>
                    <measurement group_id="O3" value="76.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsening of 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67"/>
                    <measurement group_id="O2" value="16.67"/>
                    <measurement group_id="O3" value="17.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsening of 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsening of 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsening of 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5.56"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Electrocardiogram (EKG)</title>
        <description>Mean corrected QT interval (QTc) by study week and treatment.</description>
        <time_frame>Once during Evaluation and once at Treatment Week 6</time_frame>
        <population>50 participants who completed the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin/Placebo-galantamine</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine/Placebo-oxytocin</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo-galantamine /Placebo-oxytocin</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Electrocardiogram (EKG)</title>
          <description>Mean corrected QT interval (QTc) by study week and treatment.</description>
          <population>50 participants who completed the trial.</population>
          <units>QTc</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Evaluation Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416.5" spread="23.1"/>
                    <measurement group_id="O2" value="419.0" spread="26.6"/>
                    <measurement group_id="O3" value="422.6" spread="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="415.7" spread="28.3"/>
                    <measurement group_id="O2" value="408.1" spread="27.2"/>
                    <measurement group_id="O3" value="423.8" spread="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="20.7"/>
                    <measurement group_id="O2" value="-10.2" spread="18.3"/>
                    <measurement group_id="O3" value="0.9" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Barnes Akathisia Scale (BAS) - Global Score</title>
        <description>For each subject, the largest increase from baseline in the global akathisia score at any visit during follow-up was calculated. The global akathisia score ranges from &quot;0=Absent&quot; to &quot;5=Severe Akathisia&quot;. Higher scores indicate a more severe global rating of akathisia.</description>
        <time_frame>Treatment Week 0 and Week 6</time_frame>
        <population>50 participants who completed the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin/Placebo-galantamine</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine/Placebo-oxytocin</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo-galantamine /Placebo-oxytocin</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Barnes Akathisia Scale (BAS) - Global Score</title>
          <description>For each subject, the largest increase from baseline in the global akathisia score at any visit during follow-up was calculated. The global akathisia score ranges from &quot;0=Absent&quot; to &quot;5=Severe Akathisia&quot;. Higher scores indicate a more severe global rating of akathisia.</description>
          <population>50 participants who completed the trial.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No worsening (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.33"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="94.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsening of 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Oxytocin Levels</title>
        <description>Blood Oxytocin Levels by Treatment and Visit</description>
        <time_frame>Treatment Week 0 and Week 6</time_frame>
        <population>Of the 56 participants exposed to study drug, 3 withdrew before any efficacy data was collected, leaving 53 for whom at least some interim efficacy data was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin/Placebo-galantamine</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine/Placebo-oxytocin</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo-galantamine /Placebo-oxytocin</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Oxytocin Levels</title>
          <description>Blood Oxytocin Levels by Treatment and Visit</description>
          <population>Of the 56 participants exposed to study drug, 3 withdrew before any efficacy data was collected, leaving 53 for whom at least some interim efficacy data was collected.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.22" spread="15.52"/>
                    <measurement group_id="O2" value="13.76" spread="6.96"/>
                    <measurement group_id="O3" value="14.69" spread="7.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.22" spread="17.02"/>
                    <measurement group_id="O2" value="10.11" spread="3.42"/>
                    <measurement group_id="O3" value="13.21" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.88" spread="14.09"/>
                    <measurement group_id="O2" value="-2.99" spread="5.2"/>
                    <measurement group_id="O3" value="-1.73" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Measures - ALT/SGPT</title>
        <description>Alanine transaminase/serum glutamic-pyruvic transaminase (ALT/SGPT) blood levels by treatment group and visit.</description>
        <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
        <population>Available participant lab data at Evaluation and Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin/Placebo-galantamine</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine/Placebo-oxytocin</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo-galantamine /Placebo-oxytocin</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Measures - ALT/SGPT</title>
          <description>Alanine transaminase/serum glutamic-pyruvic transaminase (ALT/SGPT) blood levels by treatment group and visit.</description>
          <population>Available participant lab data at Evaluation and Week 6.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Evaluation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.87" spread="8.68"/>
                    <measurement group_id="O2" value="31.26" spread="22.93"/>
                    <measurement group_id="O3" value="27.40" spread="19.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.67" spread="13.03"/>
                    <measurement group_id="O2" value="28.90" spread="22.81"/>
                    <measurement group_id="O3" value="27.74" spread="16.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.15" spread="10.20"/>
                    <measurement group_id="O2" value="-2.65" spread="6.14"/>
                    <measurement group_id="O3" value="0.31" spread="8.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Measures - AST/SGOT</title>
        <description>Aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) blood levels by treatment group and visit.</description>
        <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
        <population>Available participant lab data at Evaluation and Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin/Placebo-galantamine</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine/Placebo-oxytocin</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo-galantamine /Placebo-oxytocin</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Measures - AST/SGOT</title>
          <description>Aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) blood levels by treatment group and visit.</description>
          <population>Available participant lab data at Evaluation and Week 6.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Evaluation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.87" spread="5.46"/>
                    <measurement group_id="O2" value="22.68" spread="9.68"/>
                    <measurement group_id="O3" value="22.50" spread="9.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.27" spread="8.94"/>
                    <measurement group_id="O2" value="21.45" spread="10.16"/>
                    <measurement group_id="O3" value="23.58" spread="9.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.46" spread="4.20"/>
                    <measurement group_id="O2" value="-1.53" spread="8.13"/>
                    <measurement group_id="O3" value="1.00" spread="5.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Measures - Alkaline Phosphatase</title>
        <description>Alkaline phosphatase blood level by treatment group and visit.</description>
        <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
        <population>Available participant lab data at Evaluation at Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin/Placebo-galantamine</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine/Placebo-oxytocin</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo-galantamine /Placebo-oxytocin</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Measures - Alkaline Phosphatase</title>
          <description>Alkaline phosphatase blood level by treatment group and visit.</description>
          <population>Available participant lab data at Evaluation at Week 6.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Evaluation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.47" spread="21.56"/>
                    <measurement group_id="O2" value="83.42" spread="16.29"/>
                    <measurement group_id="O3" value="86.40" spread="23.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.73" spread="31.09"/>
                    <measurement group_id="O2" value="82.50" spread="20.50"/>
                    <measurement group_id="O3" value="88.95" spread="29.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.77" spread="15.81"/>
                    <measurement group_id="O2" value="0.88" spread="10.29"/>
                    <measurement group_id="O3" value="1.19" spread="10.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Measures - Calcium</title>
        <description>Calcium blood levels by treatment group and visit.</description>
        <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
        <population>Available participant lab data at Evaluation and Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Measures - Calcium</title>
          <description>Calcium blood levels by treatment group and visit.</description>
          <population>Available participant lab data at Evaluation and Week 6.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Evaluation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.53" spread="0.33"/>
                    <measurement group_id="O2" value="9.36" spread="0.31"/>
                    <measurement group_id="O3" value="9.58" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.57" spread="0.32"/>
                    <measurement group_id="O2" value="9.23" spread="0.31"/>
                    <measurement group_id="O3" value="9.54" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.33"/>
                    <measurement group_id="O2" value="-0.16" spread="0.21"/>
                    <measurement group_id="O3" value="-0.03" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Measures - Sodium</title>
        <description>Sodium blood levels by treatment group and visit.</description>
        <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
        <population>Available participant lab data at Evaluation and Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Measures - Sodium</title>
          <description>Sodium blood levels by treatment group and visit.</description>
          <population>Available participant lab data at Evaluation and Week 6.</population>
          <units>mE/qL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Evaluation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.53" spread="2.29"/>
                    <measurement group_id="O2" value="139.53" spread="2.89"/>
                    <measurement group_id="O3" value="137.30" spread="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.53" spread="3.02"/>
                    <measurement group_id="O2" value="139.15" spread="2.16"/>
                    <measurement group_id="O3" value="137.47" spread="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="1.63"/>
                    <measurement group_id="O2" value="-0.53" spread="3.22"/>
                    <measurement group_id="O3" value="0.31" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Measures - Potassium</title>
        <description>Potassium blood levels by treatment group and visit.</description>
        <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
        <population>Available participant lab data at Evaluation and Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Measures - Potassium</title>
          <description>Potassium blood levels by treatment group and visit.</description>
          <population>Available participant lab data at Evaluation and Week 6.</population>
          <units>mE/qL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Evaluation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.20" spread="0.47"/>
                    <measurement group_id="O2" value="4.14" spread="0.31"/>
                    <measurement group_id="O3" value="4.17" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.07" spread="0.32"/>
                    <measurement group_id="O2" value="4.01" spread="0.27"/>
                    <measurement group_id="O3" value="4.16" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.43"/>
                    <measurement group_id="O2" value="-0.15" spread="0.22"/>
                    <measurement group_id="O3" value="0.00" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Measures - Chloride</title>
        <description>Chloride blood levels by treatment group and visit.</description>
        <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
        <population>Available participant lab data for Evaluation and Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Measures - Chloride</title>
          <description>Chloride blood levels by treatment group and visit.</description>
          <population>Available participant lab data for Evaluation and Week 6.</population>
          <units>mE/qL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Evaluation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.60" spread="2.95"/>
                    <measurement group_id="O2" value="102.79" spread="3.41"/>
                    <measurement group_id="O3" value="100.15" spread="4.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.53" spread="3.54"/>
                    <measurement group_id="O2" value="102.90" spread="2.63"/>
                    <measurement group_id="O3" value="100.47" spread="3.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="1.89"/>
                    <measurement group_id="O2" value="-0.06" spread="2.70"/>
                    <measurement group_id="O3" value="0.56" spread="2.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Measures - CO2</title>
        <description>Carbon Dioxide (CO2) blood levels by treatment group and visit.</description>
        <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
        <population>Available participant lab data for Evaluation and Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Measures - CO2</title>
          <description>Carbon Dioxide (CO2) blood levels by treatment group and visit.</description>
          <population>Available participant lab data for Evaluation and Week 6.</population>
          <units>mE/qL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Evaluation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.47" spread="2.13"/>
                    <measurement group_id="O2" value="22.42" spread="3.01"/>
                    <measurement group_id="O3" value="23.40" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.27" spread="2.09"/>
                    <measurement group_id="O2" value="22.50" spread="2.33"/>
                    <measurement group_id="O3" value="22.83" spread="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="2.21"/>
                    <measurement group_id="O2" value="-0.06" spread="2.77"/>
                    <measurement group_id="O3" value="-0.20" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Measures - Cholesterol</title>
        <description>Total cholesterol blood levels by treatment group and visit.</description>
        <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
        <population>Available participant lab data for Evaluation and Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Measures - Cholesterol</title>
          <description>Total cholesterol blood levels by treatment group and visit.</description>
          <population>Available participant lab data for Evaluation and Week 6.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Evaluation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.18" spread="19.18"/>
                    <measurement group_id="O2" value="166.07" spread="35.98"/>
                    <measurement group_id="O3" value="179.60" spread="37.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.93" spread="22.57"/>
                    <measurement group_id="O2" value="162.93" spread="22.57"/>
                    <measurement group_id="O3" value="177.33" spread="36.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="12.61"/>
                    <measurement group_id="O2" value="-2.40" spread="15.87"/>
                    <measurement group_id="O3" value="-11.44" spread="31.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Measures - HDL</title>
        <description>High-density lipoprotein (HDL) blood levels by treatment group and visit.</description>
        <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
        <population>Available participant data from Evaluation and Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Measures - HDL</title>
          <description>High-density lipoprotein (HDL) blood levels by treatment group and visit.</description>
          <population>Available participant data from Evaluation and Week 6.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Evaluation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.09" spread="12.31"/>
                    <measurement group_id="O2" value="45.50" spread="14.43"/>
                    <measurement group_id="O3" value="41.14" spread="10.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.31" spread="14.07"/>
                    <measurement group_id="O2" value="43.64" spread="11.62"/>
                    <measurement group_id="O3" value="41.42" spread="10.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="6.31"/>
                    <measurement group_id="O2" value="2.11" spread="3.69"/>
                    <measurement group_id="O3" value="-1.67" spread="4.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Measures - LDL</title>
        <description>Low-density lipoprotein (LDL) blood levels by treatment group and visit.</description>
        <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
        <population>Available participant lab data for Evaluation and Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Measures - LDL</title>
          <description>Low-density lipoprotein (LDL) blood levels by treatment group and visit.</description>
          <population>Available participant lab data for Evaluation and Week 6.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Evaluation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.36" spread="25.02"/>
                    <measurement group_id="O2" value="91.25" spread="20.42"/>
                    <measurement group_id="O3" value="105.79" spread="37.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.92" spread="28.72"/>
                    <measurement group_id="O2" value="92.29" spread="19.51"/>
                    <measurement group_id="O3" value="103.73" spread="33.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="11.58"/>
                    <measurement group_id="O2" value="-1.38" spread="14.92"/>
                    <measurement group_id="O3" value="-13.00" spread="26.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Measures - Triglycerides</title>
        <description>Triglyceride blood levels by treatment group and visit.</description>
        <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
        <population>Available participant lab data for Evaluation and Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Measures - Triglycerides</title>
          <description>Triglyceride blood levels by treatment group and visit.</description>
          <population>Available participant lab data for Evaluation and Week 6.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Evaluation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.55" spread="60.32"/>
                    <measurement group_id="O2" value="155.20" spread="118.82"/>
                    <measurement group_id="O3" value="163.47" spread="102.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.79" spread="69.57"/>
                    <measurement group_id="O2" value="142.29" spread="99.53"/>
                    <measurement group_id="O3" value="162.17" spread="102.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.00" spread="40.14"/>
                    <measurement group_id="O2" value="-39.30" spread="77.44"/>
                    <measurement group_id="O3" value="1.22" spread="49.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Measures - VLDL</title>
        <description>Very low density lipoprotein (VLDL) blood levels by treatment group and visit.</description>
        <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
        <population>Available participant lab data for Evaluation and Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Measures - VLDL</title>
          <description>Very low density lipoprotein (VLDL) blood levels by treatment group and visit.</description>
          <population>Available participant lab data for Evaluation and Week 6.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Evaluation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.73" spread="12.04"/>
                    <measurement group_id="O2" value="22.00" spread="10.49"/>
                    <measurement group_id="O3" value="33.17" spread="22.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.75" spread="13.93"/>
                    <measurement group_id="O2" value="23.62" spread="9.50"/>
                    <measurement group_id="O3" value="28.00" spread="14.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.80" spread="8.13"/>
                    <measurement group_id="O2" value="-3.13" spread="6.31"/>
                    <measurement group_id="O3" value="-0.43" spread="11.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Measures - Glucose</title>
        <description>Glucose blood levels by treatment group and visit.</description>
        <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
        <population>Available participant lab data for Evaluation and Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Measures - Glucose</title>
          <description>Glucose blood levels by treatment group and visit.</description>
          <population>Available participant lab data for Evaluation and Week 6.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Evaluation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.07" spread="47.12"/>
                    <measurement group_id="O2" value="98.61" spread="15.50"/>
                    <measurement group_id="O3" value="103.00" spread="21.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.67" spread="19.53"/>
                    <measurement group_id="O2" value="102.13" spread="18.13"/>
                    <measurement group_id="O3" value="112.31" spread="33.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.23" spread="30.91"/>
                    <measurement group_id="O2" value="2.00" spread="20.64"/>
                    <measurement group_id="O3" value="9.77" spread="16.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Measures - Albumin</title>
        <description>Albumin blood levels by treatment group and visit.</description>
        <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
        <population>Available participant lab data for Evaluation and Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Measures - Albumin</title>
          <description>Albumin blood levels by treatment group and visit.</description>
          <population>Available participant lab data for Evaluation and Week 6.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Evaluation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.39" spread="0.24"/>
                    <measurement group_id="O2" value="4.27" spread="0.31"/>
                    <measurement group_id="O3" value="4.35" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38" spread="0.25"/>
                    <measurement group_id="O2" value="4.23" spread="0.27"/>
                    <measurement group_id="O3" value="4.37" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.23"/>
                    <measurement group_id="O2" value="-0.03" spread="0.35"/>
                    <measurement group_id="O3" value="0.03" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Measures - Globulin</title>
        <description>Globulin blood levels by treatment group and visit.</description>
        <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
        <population>Available participant lab data for Evaluation and Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Measures - Globulin</title>
          <description>Globulin blood levels by treatment group and visit.</description>
          <population>Available participant lab data for Evaluation and Week 6.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Evaluation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" spread="0.40"/>
                    <measurement group_id="O2" value="2.81" spread="0.42"/>
                    <measurement group_id="O3" value="2.82" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.58" spread="0.54"/>
                    <measurement group_id="O2" value="2.66" spread="0.51"/>
                    <measurement group_id="O3" value="2.78" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.63"/>
                    <measurement group_id="O2" value="-0.18" spread="0.38"/>
                    <measurement group_id="O3" value="-0.09" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Measures - A/G Ratio</title>
        <description>Albumin to Globulin (A/G) ratio in the blood by treatment group and visit.</description>
        <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
        <population>Available participant date for Evaluation and Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Measures - A/G Ratio</title>
          <description>Albumin to Globulin (A/G) ratio in the blood by treatment group and visit.</description>
          <population>Available participant date for Evaluation and Week 6.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Evaluation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="0.29"/>
                    <measurement group_id="O2" value="1.58" spread="0.27"/>
                    <measurement group_id="O3" value="1.57" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="0.64"/>
                    <measurement group_id="O2" value="1.62" spread="0.31"/>
                    <measurement group_id="O3" value="1.60" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.22"/>
                    <measurement group_id="O2" value="0.05" spread="0.18"/>
                    <measurement group_id="O3" value="0.07" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Measures - Bilirubin</title>
        <description>Bilirubin blood level by treatment group and visit.</description>
        <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
        <population>Available participant data for Evaluation and Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Measures - Bilirubin</title>
          <description>Bilirubin blood level by treatment group and visit.</description>
          <population>Available participant data for Evaluation and Week 6.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Evaluation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.29"/>
                    <measurement group_id="O2" value="0.35" spread="0.19"/>
                    <measurement group_id="O3" value="0.40" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.24"/>
                    <measurement group_id="O2" value="0.39" spread="0.24"/>
                    <measurement group_id="O3" value="0.38" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.13"/>
                    <measurement group_id="O2" value="0.05" spread="0.23"/>
                    <measurement group_id="O3" value="0.03" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Measures - Protein</title>
        <description>Protein blood level by treatment group and visit.</description>
        <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
        <population>Available participant data for Evaluation and Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Measures - Protein</title>
          <description>Protein blood level by treatment group and visit.</description>
          <population>Available participant data for Evaluation and Week 6.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Evaluation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.10" spread="0.32"/>
                    <measurement group_id="O2" value="7.07" spread="0.41"/>
                    <measurement group_id="O3" value="7.17" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.14" spread="0.42"/>
                    <measurement group_id="O2" value="6.92" spread="0.45"/>
                    <measurement group_id="O3" value="7.15" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.30"/>
                    <measurement group_id="O2" value="-0.13" spread="0.34"/>
                    <measurement group_id="O3" value="-0.04" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Measures - BUN</title>
        <description>BUN blood level by treatment group and visit.</description>
        <time_frame>Once during evaluation and once at the end of 6 weeks of study treatment</time_frame>
        <population>Available participant data for Evaluation and Week 6.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Measures - BUN</title>
          <description>BUN blood level by treatment group and visit.</description>
          <population>Available participant data for Evaluation and Week 6.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Evaluation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.80" spread="4.92"/>
                    <measurement group_id="O2" value="10.74" spread="3.18"/>
                    <measurement group_id="O3" value="11.95" spread="4.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.73" spread="4.85"/>
                    <measurement group_id="O2" value="11.55" spread="3.41"/>
                    <measurement group_id="O3" value="12.00" spread="4.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="2.82"/>
                    <measurement group_id="O2" value="1.06" spread="3.07"/>
                    <measurement group_id="O3" value="-0.06" spread="3.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Abdominal Pain</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Abdominal Pain&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Abdominal Pain</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Abdominal Pain&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="5.0"/>
                    <measurement group_id="O3" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Anorexia</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Anorexia&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Anorexia</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Anorexia&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Bruising Easily</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Bruising Easily&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Bruising Easily</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Bruising Easily&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Constipation</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Constipation&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Constipation</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Constipation&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Diarrhea</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Diarrhea&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Diarrhea</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Diarrhea&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="30.0"/>
                    <measurement group_id="O3" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Dizziness</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Dizziness&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Dizziness</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Dizziness&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="30.0"/>
                    <measurement group_id="O3" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Dry Eye</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Dry Eye&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment minus 6 participants who had missing &quot;dry eye&quot; data.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Dry Eye</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Dry Eye&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment minus 6 participants who had missing &quot;dry eye&quot; data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Dry Mouth</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Dry Mouth&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Dry Mouth</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Dry Mouth&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="5.0"/>
                    <measurement group_id="O3" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Enuresis</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Enuresis&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Enuresis</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Enuresis&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="5.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Excessive Tearing of the Eye</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Excessive Tearing of the Eye&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment minus 6 participants who had missing &quot;excessive tearing of the eye&quot; data.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Excessive Tearing of the Eye</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Excessive Tearing of the Eye&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment minus 6 participants who had missing &quot;excessive tearing of the eye&quot; data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="5.6"/>
                    <measurement group_id="O3" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Fever</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Fever&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Fever</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Fever&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="5.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Headache</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Headache&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Headache</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Headache&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Hyperhydrosis</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Hyperhydrosis&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment minus 6 participants who had missing &quot;Hyperhydrosis&quot; data.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Hyperhydrosis</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Hyperhydrosis&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment minus 6 participants who had missing &quot;Hyperhydrosis&quot; data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Hypersalivation</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Hypersalivation&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Hypersalivation</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Hypersalivation&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="15.0"/>
                    <measurement group_id="O3" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Insomnia</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Insomnia&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Insomnia</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Insomnia&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Malaise</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Malaise&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Malaise</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Malaise&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Mucosal Ulceration</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Mucosal Ulceration&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Mucosal Ulceration</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Mucosal Ulceration&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="5.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Nasal Irritation</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Nasal Irritation&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment minus 6 participants who had missing &quot;nasal irritation&quot; data.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Nasal Irritation</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Nasal Irritation&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment minus 6 participants who had missing &quot;nasal irritation&quot; data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Nausea</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Nausea&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Nausea</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Nausea&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="15.0"/>
                    <measurement group_id="O3" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Rash</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Rash&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Rash</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Rash&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Restlessness</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Restlessness&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Restlessness</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Restlessness&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Sedation</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Sedation&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Sedation</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Sedation&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="15.0"/>
                    <measurement group_id="O3" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Sore Throat</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Sore Throat&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Sore Throat</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Sore Throat&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Stiffness</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Stiffness&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Stiffness</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Stiffness&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Tinnitus</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Tinnitus&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Tinnitus</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Tinnitus&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Tremor</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Tremor&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Tremor</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Tremor&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="15.0"/>
                    <measurement group_id="O3" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Urticaria</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Urticaria&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Urticaria</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Urticaria&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="15.0"/>
                    <measurement group_id="O3" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Uterine Contractions</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Uterine Contractions&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Female participants</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Uterine Contractions</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Uterine Contractions&quot; rating on the SEC, by Treatment Group.</description>
          <population>Female participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Vomiting</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Vomiting&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Vomiting</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Vomiting&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="5.0"/>
                    <measurement group_id="O3" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Weight Loss</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Weight Loss&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Weight Loss</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Weight Loss&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="5.0"/>
                    <measurement group_id="O3" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Checklist (SEC) - Wheezing</title>
        <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Wheezing&quot; rating on the SEC, by Treatment Group.</description>
        <time_frame>Weekly for 6 weeks</time_frame>
        <population>Safety data for 56 participants exposed to study treatment minus 6 participants with missing &quot;wheezing&quot; data.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Checklist (SEC) - Wheezing</title>
          <description>Percentage of participants with new onset or worsening compared to baseline of &quot;Wheezing&quot; rating on the SEC, by Treatment Group.</description>
          <population>Safety data for 56 participants exposed to study treatment minus 6 participants with missing &quot;wheezing&quot; data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="5.6"/>
                    <measurement group_id="O3" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Assessment Battery (MCCB) - Composite Score</title>
        <description>MCCB Composite Score by Week ranging from -10-100 with a higher score indicating a better outcome.</description>
        <time_frame>Once at Treatment Week 0 (baseline) and again at Treatment Week 6 (end of treatment).</time_frame>
        <population>Cognitive data was collected at baseline and week 6, so only those participants who got to week 6 appear in cognitive outcome analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin/Placebo-galantamine</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine/Placebo-oxytocin</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo-galantamine /Placebo-oxytocin</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Assessment Battery (MCCB) - Composite Score</title>
          <description>MCCB Composite Score by Week ranging from -10-100 with a higher score indicating a better outcome.</description>
          <population>Cognitive data was collected at baseline and week 6, so only those participants who got to week 6 appear in cognitive outcome analyses.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9" spread="13.0"/>
                    <measurement group_id="O2" value="24.5" spread="9.7"/>
                    <measurement group_id="O3" value="28.2" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2" spread="14.1"/>
                    <measurement group_id="O2" value="26.2" spread="11.1"/>
                    <measurement group_id="O3" value="28.9" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="3.9"/>
                    <measurement group_id="O2" value="1.7" spread="4.0"/>
                    <measurement group_id="O3" value="0.7" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Assessment Battery (MCCB) - Attention Vigilance</title>
        <description>MCCB Attention Vigilance domain score by week calculated from the Continuous Performance Test, Identical Pairs version. The domain score scale is 20-80, with higher scores indicating a better outcome.</description>
        <time_frame>Once at Treatment Week 0 (baseline) and again at Treatment Week 6 (end of treatment).</time_frame>
        <population>Cognitive data was collected at baseline and week 6, so only those participants who got to week 6 appear in cognitive outcome analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Assessment Battery (MCCB) - Attention Vigilance</title>
          <description>MCCB Attention Vigilance domain score by week calculated from the Continuous Performance Test, Identical Pairs version. The domain score scale is 20-80, with higher scores indicating a better outcome.</description>
          <population>Cognitive data was collected at baseline and week 6, so only those participants who got to week 6 appear in cognitive outcome analyses.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9" spread="8.8"/>
                    <measurement group_id="O2" value="33.5" spread="14.5"/>
                    <measurement group_id="O3" value="37.2" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.5" spread="11.3"/>
                    <measurement group_id="O2" value="34.5" spread="13.6"/>
                    <measurement group_id="O3" value="35.1" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="5.8"/>
                    <measurement group_id="O2" value="1.1" spread="6.9"/>
                    <measurement group_id="O3" value="-2.1" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Assessment Battery (MCCB) - Processing Speed</title>
        <description>MCCB Processing Speed domain score by week calculated from the Trail Making Test- Part A, Brief Assessment of Cognition in Schizophrenia- symbol coding subtest, and the Category fluency test- animal naming. The domain score scale is 20-80, with higher scores indicating a better outcome.</description>
        <time_frame>Once at Treatment Week 0 (baseline) and again at Treatment Week 6 (end of treatment).</time_frame>
        <population>Cognitive data was collected at baseline and week 6, so only those participants who got to week 6 appear in cognitive outcome analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Assessment Battery (MCCB) - Processing Speed</title>
          <description>MCCB Processing Speed domain score by week calculated from the Trail Making Test- Part A, Brief Assessment of Cognition in Schizophrenia- symbol coding subtest, and the Category fluency test- animal naming. The domain score scale is 20-80, with higher scores indicating a better outcome.</description>
          <population>Cognitive data was collected at baseline and week 6, so only those participants who got to week 6 appear in cognitive outcome analyses.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5" spread="13.1"/>
                    <measurement group_id="O2" value="31.9" spread="11.7"/>
                    <measurement group_id="O3" value="34.0" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2" spread="11.6"/>
                    <measurement group_id="O2" value="35.4" spread="8.6"/>
                    <measurement group_id="O3" value="35.6" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="4.3"/>
                    <measurement group_id="O2" value="3.5" spread="5.6"/>
                    <measurement group_id="O3" value="1.6" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Assessment Battery (MCCB) - Reasoning/Problem Solving</title>
        <description>MCCB Reasoning/Problem Solving domain score by week calculated from the Neuropsychological Assessment Battery- mazes subtest. The domain score scale is 20-80, with higher scores indicating a better outcome.</description>
        <time_frame>Once at Treatment Week 0 (baseline) and again at Treatment Week 6 (end of treatment).</time_frame>
        <population>Cognitive data was collected at baseline and week 6, so only those participants who got to week 6 appear in cognitive outcome analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Assessment Battery (MCCB) - Reasoning/Problem Solving</title>
          <description>MCCB Reasoning/Problem Solving domain score by week calculated from the Neuropsychological Assessment Battery- mazes subtest. The domain score scale is 20-80, with higher scores indicating a better outcome.</description>
          <population>Cognitive data was collected at baseline and week 6, so only those participants who got to week 6 appear in cognitive outcome analyses.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.7" spread="10.8"/>
                    <measurement group_id="O2" value="39.3" spread="6.8"/>
                    <measurement group_id="O3" value="41.4" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7" spread="9.4"/>
                    <measurement group_id="O2" value="42.9" spread="8.3"/>
                    <measurement group_id="O3" value="41.7" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="8.1"/>
                    <measurement group_id="O2" value="3.7" spread="5.1"/>
                    <measurement group_id="O3" value="0.3" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Assessment Battery (MCCB) - Social Cognition</title>
        <description>MCCB Social Cognition domain score by week calculated from the Mayer-Salovey-Caruso Emotional Intelligence Test- managing emotions branch. The domain score scale is 20-80, with higher scores indicating a better outcome.</description>
        <time_frame>Once at Treatment Week 0 (baseline) and again at Treatment Week 6 (end of treatment).</time_frame>
        <population>Cognitive data was collected at baseline and week 6, so only those participants who got to week 6 appear in cognitive outcome analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Assessment Battery (MCCB) - Social Cognition</title>
          <description>MCCB Social Cognition domain score by week calculated from the Mayer-Salovey-Caruso Emotional Intelligence Test- managing emotions branch. The domain score scale is 20-80, with higher scores indicating a better outcome.</description>
          <population>Cognitive data was collected at baseline and week 6, so only those participants who got to week 6 appear in cognitive outcome analyses.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7" spread="9.7"/>
                    <measurement group_id="O2" value="32.8" spread="10.4"/>
                    <measurement group_id="O3" value="30.4" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5" spread="13.0"/>
                    <measurement group_id="O2" value="29.6" spread="10.0"/>
                    <measurement group_id="O3" value="32.8" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="7.6"/>
                    <measurement group_id="O2" value="-3.2" spread="4.6"/>
                    <measurement group_id="O3" value="2.4" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Assessment Battery (MCCB) - Verbal Learning</title>
        <description>MCCB Verbal Learning domain score by week calculated from the Hopkins Verbal Learning Test—Revised, immediate recall (three learning trials only). The domain score scale is 20-80, with higher scores indicating a better outcome.</description>
        <time_frame>Once at Treatment Week 0 (baseline) and again at Treatment Week 6 (end of treatment).</time_frame>
        <population>Cognitive data was collected at baseline and week 6, so only those participants who got to week 6 appear in cognitive outcome analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Assessment Battery (MCCB) - Verbal Learning</title>
          <description>MCCB Verbal Learning domain score by week calculated from the Hopkins Verbal Learning Test—Revised, immediate recall (three learning trials only). The domain score scale is 20-80, with higher scores indicating a better outcome.</description>
          <population>Cognitive data was collected at baseline and week 6, so only those participants who got to week 6 appear in cognitive outcome analyses.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="8.5"/>
                    <measurement group_id="O2" value="33.4" spread="5.0"/>
                    <measurement group_id="O3" value="36.5" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7" spread="9.9"/>
                    <measurement group_id="O2" value="35.8" spread="7.7"/>
                    <measurement group_id="O3" value="36.4" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="5.4"/>
                    <measurement group_id="O2" value="2.4" spread="5.8"/>
                    <measurement group_id="O3" value="-0.1" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Assessment Battery (MCCB) - Visual Learning</title>
        <description>MCCB Visual Learning domain score by week calculated from the Brief Visuospatial Memory Test—Revised. The domain score scale is 20-80, with higher scores indicating a better outcome.</description>
        <time_frame>Once at Treatment Week 0 (baseline) and again at Treatment Week 6 (end of treatment).</time_frame>
        <population>Cognitive data was collected at baseline and week 6, so only those participants who got to week 6 appear in cognitive outcome analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Assessment Battery (MCCB) - Visual Learning</title>
          <description>MCCB Visual Learning domain score by week calculated from the Brief Visuospatial Memory Test—Revised. The domain score scale is 20-80, with higher scores indicating a better outcome.</description>
          <population>Cognitive data was collected at baseline and week 6, so only those participants who got to week 6 appear in cognitive outcome analyses.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8" spread="14.3"/>
                    <measurement group_id="O2" value="37.2" spread="10.8"/>
                    <measurement group_id="O3" value="35.1" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" spread="16.6"/>
                    <measurement group_id="O2" value="33.7" spread="10.0"/>
                    <measurement group_id="O3" value="34.2" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="6.2"/>
                    <measurement group_id="O2" value="-3.4" spread="8.3"/>
                    <measurement group_id="O3" value="-0.9" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Assessment Battery (MCCB) - Working Memory</title>
        <description>MCCB Working Memory domain score by week calculated from the Wechsler Memory Scale, 3rd ed., spatial span subtest. The domain score scale is 20-80, with higher scores indicating a better outcome.</description>
        <time_frame>Once at Treatment Week 0 (baseline) and again at Treatment Week 6 (end of treatment).</time_frame>
        <population>Cognitive data was collected at baseline and week 6, so only those participants who got to week 6 appear in cognitive outcome analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Assessment Battery (MCCB) - Working Memory</title>
          <description>MCCB Working Memory domain score by week calculated from the Wechsler Memory Scale, 3rd ed., spatial span subtest. The domain score scale is 20-80, with higher scores indicating a better outcome.</description>
          <population>Cognitive data was collected at baseline and week 6, so only those participants who got to week 6 appear in cognitive outcome analyses.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.7" spread="10.7"/>
                    <measurement group_id="O2" value="33.7" spread="9.6"/>
                    <measurement group_id="O3" value="35.3" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8" spread="11.1"/>
                    <measurement group_id="O2" value="34.7" spread="10.4"/>
                    <measurement group_id="O3" value="38.1" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="6.5"/>
                    <measurement group_id="O2" value="0.9" spread="7.7"/>
                    <measurement group_id="O3" value="2.8" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive and Negative Affect Schedule (PANAS) - Negative</title>
        <description>Participant reported responses after Brief Role Play rating how they felt during the role plays. Participants rated 12 negative affect items on a scale of 1-5, with 1 being &quot;very slightly or not at all&quot; and 5 being &quot;extremely&quot;. The minimum score for this measure is 12 and the maximum score is 60. Higher scores indicate a higher rate of negative affect during the role plays.</description>
        <time_frame>Treatment Week 0 and Week 6</time_frame>
        <population>Role play data was collected at baseline and week 6, so only those participants who completed the role play at week 6 appear in these outcome analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Positive and Negative Affect Schedule (PANAS) - Negative</title>
          <description>Participant reported responses after Brief Role Play rating how they felt during the role plays. Participants rated 12 negative affect items on a scale of 1-5, with 1 being &quot;very slightly or not at all&quot; and 5 being &quot;extremely&quot;. The minimum score for this measure is 12 and the maximum score is 60. Higher scores indicate a higher rate of negative affect during the role plays.</description>
          <population>Role play data was collected at baseline and week 6, so only those participants who completed the role play at week 6 appear in these outcome analyses.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" spread="7.8"/>
                    <measurement group_id="O2" value="18.2" spread="7.0"/>
                    <measurement group_id="O3" value="20.2" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" spread="7.7"/>
                    <measurement group_id="O2" value="18.0" spread="5.6"/>
                    <measurement group_id="O3" value="18.9" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Week 0 at Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="5.7"/>
                    <measurement group_id="O2" value="-0.2" spread="6.8"/>
                    <measurement group_id="O3" value="-1.3" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive and Negative Affect Schedule (PANAS) - Positive</title>
        <description>Participant reported responses after Brief Role Play rating how they felt during the role plays. Participants rated 12 positive affect items on a scale of 1-5, with 1 being &quot;very slightly or not at all&quot; and 5 being &quot;extremely&quot;. The minimum score for this measure is 12 and the maximum score is 60. Higher scores indicate a higher rate of positive affect during the role plays.</description>
        <time_frame>Treatment Week 0 and Week 6</time_frame>
        <population>Role play data was collected at baseline and week 6, so only those participants who completed the role play at week 6 appear in these outcome analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Positive and Negative Affect Schedule (PANAS) - Positive</title>
          <description>Participant reported responses after Brief Role Play rating how they felt during the role plays. Participants rated 12 positive affect items on a scale of 1-5, with 1 being &quot;very slightly or not at all&quot; and 5 being &quot;extremely&quot;. The minimum score for this measure is 12 and the maximum score is 60. Higher scores indicate a higher rate of positive affect during the role plays.</description>
          <population>Role play data was collected at baseline and week 6, so only those participants who completed the role play at week 6 appear in these outcome analyses.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1" spread="8.6"/>
                    <measurement group_id="O2" value="37.0" spread="12.3"/>
                    <measurement group_id="O3" value="42.5" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5" spread="12.8"/>
                    <measurement group_id="O2" value="39.5" spread="12.3"/>
                    <measurement group_id="O3" value="40.8" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Week 0 at Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="10.8"/>
                    <measurement group_id="O2" value="2.5" spread="11.4"/>
                    <measurement group_id="O3" value="-1.6" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reactions to Partner</title>
        <description>Participant reported responses after Brief Role Play. The Reactions to Partner item was calculated by totaling responses to 7 scales. Each scale score ranges from 1-5, which 1 being &quot;completely agree&quot; and 5 being &quot;completely disagree&quot;. The minimum score for this measure is 7 and the maximum score is 35. Higher responses indicate a more negative reaction to their role play partner.</description>
        <time_frame>Treatment Week 0 and Week 6</time_frame>
        <population>Role play data was collected at baseline and week 6, so only those participants who completed the role play at week 6 appear in these outcome analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Reactions to Partner</title>
          <description>Participant reported responses after Brief Role Play. The Reactions to Partner item was calculated by totaling responses to 7 scales. Each scale score ranges from 1-5, which 1 being &quot;completely agree&quot; and 5 being &quot;completely disagree&quot;. The minimum score for this measure is 7 and the maximum score is 35. Higher responses indicate a more negative reaction to their role play partner.</description>
          <population>Role play data was collected at baseline and week 6, so only those participants who completed the role play at week 6 appear in these outcome analyses.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" spread="4.2"/>
                    <measurement group_id="O2" value="14.4" spread="5.6"/>
                    <measurement group_id="O3" value="12.5" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" spread="3.1"/>
                    <measurement group_id="O2" value="13.9" spread="3.7"/>
                    <measurement group_id="O3" value="12.5" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Week 0 at Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="3.5"/>
                    <measurement group_id="O2" value="-0.4" spread="4.0"/>
                    <measurement group_id="O3" value="0.0" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Willingness to Interact</title>
        <description>Participant reported responses after Brief Role Play. The Willingness to Interact item calculated by totaling scores from items 1-6. Each score ranges from 1-5, with 1 being &quot;definitely willing&quot; and 5 being &quot;definitely unwilling&quot;. The minimum score for this measure is 6 and the maximum score is 30. Lower scores indicate more willingness to interact with their role play partner again in the future.</description>
        <time_frame>Treatment Week 0 and Week 6</time_frame>
        <population>Role play data was collected at baseline and week 6, so only those participants who completed the role play at week 6 appear in these outcome analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Oxytocin</title>
            <description>Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine</description>
          </group>
          <group group_id="O2">
            <title>2: Galantamine</title>
            <description>Subjects randomized to galantamine will receive galantamine and placebo-oxytocin</description>
          </group>
          <group group_id="O3">
            <title>3: Placebo</title>
            <description>Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin</description>
          </group>
        </group_list>
        <measure>
          <title>Willingness to Interact</title>
          <description>Participant reported responses after Brief Role Play. The Willingness to Interact item calculated by totaling scores from items 1-6. Each score ranges from 1-5, with 1 being &quot;definitely willing&quot; and 5 being &quot;definitely unwilling&quot;. The minimum score for this measure is 6 and the maximum score is 30. Lower scores indicate more willingness to interact with their role play partner again in the future.</description>
          <population>Role play data was collected at baseline and week 6, so only those participants who completed the role play at week 6 appear in these outcome analyses.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.67" spread="4.13"/>
                    <measurement group_id="O2" value="23.18" spread="4.22"/>
                    <measurement group_id="O3" value="24.41" spread="4.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.47" spread="3.31"/>
                    <measurement group_id="O2" value="24.24" spread="4.34"/>
                    <measurement group_id="O3" value="25.00" spread="4.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Week 0 at Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="3.82"/>
                    <measurement group_id="O2" value="1.06" spread="3.60"/>
                    <measurement group_id="O3" value="0.59" spread="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1: Oxytocin</title>
          <description>Oxytocin: 24 IU oxytocin or placebo in a total of 6 puffs (3 puffs per nostril)daily for 6 weeks</description>
        </group>
        <group group_id="E2">
          <title>2: Galantamine</title>
          <description>Galantamine or placebo Galantamine: Galantamine will be dispensed as follows: 4 mg bid x 7 days; 8mg bid x 7days, then 12 mg bid for the last 4 weeks.</description>
        </group>
        <group group_id="E3">
          <title>3: Placebo</title>
          <description>Placebo: placebo-Galantamine 1 capsules twice a day and placebo-oxytocin 3 puffs in each nostril once a day.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>hospitalization due to unrelated pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Enuresis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>William Carpenter, Jr.</name_or_title>
      <organization>Maryland Psychiatric Research Center</organization>
      <phone>410-402-7101</phone>
      <email>wcarpent@mprc.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

